realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Public ClinicalTrials.gov record NCT04981795. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Study identification
- NCT ID
- NCT04981795
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 20, 2021 (Actual)
- Primary completion
- Jan 23, 2026 (Actual)
- Completion
- Jan 23, 2026 (Actual)
- Last update posted
- Apr 27, 2026
2021 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Oncology | Birmingham | Alabama | 35211 | — |
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | — |
| University of California, Irvine Medical Center | Orange | California | 92868 | — |
| McFarland Clinic P.C. | Ames | Iowa | 50010 | — |
| Mission Cancer and Blood | Des Moines | Iowa | 50309 | — |
| Tulane Cancer Center | New Orleans | Louisiana | 70112 | — |
| American Oncology Partners of Maryland PA | Bethesda | Maryland | 20817 | — |
| University of Michigan Comprehensive Cancer Center Michigan Medicine | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960-6136 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903-2681 | — |
| Westchester Medical Center | Hawthorne | New York | 10532 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke University | Durham | North Carolina | 27705 | — |
| VA Medical Center - Durham | Durham | North Carolina | 27705 | — |
| Leo Jenkins Cancer Center/ECU School of Medicine | Greenville | North Carolina | 27858 | — |
| Mercy Medical Center | Canton | Ohio | 44708 | — |
| Ohio Health Marion Area Physicians | Marion | Ohio | 43302 | — |
| Tri County Hematology & Oncology Associates, Inc | Massillon | Ohio | 44646 | — |
| Integris Cancer Institute of Oklahoma | Oklahoma City | Oklahoma | 73142 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Lankenau Medical Center | Wynnewood | Pennsylvania | 19096 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| UW Medicine | Seattle | Washington | 98109 | — |
| Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | 98902 | — |
| Froedtert & Medical College Clinics | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04981795, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04981795 live on ClinicalTrials.gov.